Biodesix, Inc. (BDSX)
Biodesix, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Biodesix, Inc. (BDSX) is a Medical - Diagnostics & Research company based in US with a market capitalization of $129.6M. Revenue grew 24.1% year-over-year and free cash flow was negative at -$23.7M. This page tracks BDSX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 273 employees · IPO Oct 28, 2020
Valuation
Valuation & price
$14.17as of May 17, 2026· -42.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$129.6M
Market cap
24.1%
Revenue growth (YoY)
81.1%
Gross margin
-$23.7M
Free cash flow (USD)
$53.9M
Net debt
16.5%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 4, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Biodesix, Inc.'s market cap?
Biodesix, Inc. (BDSX) has a market capitalization of $129.6M.
What is BDSX's P/E ratio?
A meaningful P/E ratio is not available for BDSX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying BDSX stock?
SEC Form 4 filings show no open-market insider buys at Biodesix, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Medical - Diagnostics & Research
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.